(Estradiol + progesterone) is a Small Molecule owned by TherapeuticsMD, and is involved in 4 clinical trials, which were completed.

Bijuva (estradiol + progesterone) is an estrogen receptor agonist and progesterone receptor agonist. The hormone replacement therapy (HRT) usually involves treatment with either estrogen alone or a combination of estrogen with progesterone or progestin for the alleviation of symptoms of menopause. The natural levels of the hormones estrogen and progesterone decrease during menopause and the lower hormone levels may lead to hot flashes, vaginal dryness and thin bones. Progesterone in combination with estradiol prevents the overgrowth of cells in the lining of the uterus. The drug candidate replaces the hormones and alleviates the diseased state.

The revenue for (Estradiol + progesterone) is expected to reach a total of $439m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Estradiol + progesterone) NPV Report.

(Estradiol + progesterone) is currently owned by TherapeuticsMD.

(Estradiol + progesterone) Overview

Estradiol and progesterone (Bijuva/Bijuve) is fixed dose combination acts as hormonal replacement agent. It is formulated as soft gelatin capsules for oral route of administration. Bijuva is indicated in woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.

The drug candidate is also under development in Israel for the treatment of moderate to severe vasomotor symptoms due to menopause.

TherapeuticsMD Overview

TherapeuticsMD is an innovative pharmaceutical company. It develops products to address the unique changes and challenges women experience throughout the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company’s major products portfolio includes segesterone acetate and ethinyl estradiol, estradiol and progesterone capsules, prenatal vitamins, estradiol vaginal inserts. The company sells its products under the various brands name of VitamedMD, BocagreenMD, Annovera, Bijuva, vitaPearl, vitaTrue, vitaMedMD RediChew Rx, vitaMedMD One Rx, FOLMAX, pur-DHA, FePlus, Plant Pure Omega-3 DHA and Imvexxy. TherapeuticsMD is headquartered in Boca Raton, Florida, the US.

The company reported revenues of (US Dollars) US$87 million for the fiscal year ended December 2021 (FY2021), an increase of 34% over FY2020. The operating loss of the company was US$139.8 million in FY2021, compared to an operating loss of US$155.5 million in FY2020. The net loss of the company was US$172.4 million in FY2021, compared to a net loss of US$183.5 million in FY2020. The company reported revenues of US$20.9 million for the third quarter ended September 2022, a decrease of 26.8% over the previous quarter.

Quick View – (Estradiol + progesterone)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Estradiol + progesterone)
Administration Pathway
  • Oral
Therapeutic Areas
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.